Drug Discovery Informatics for Big Pharma: Key Webinar Insights
Collaborative Drug
MARCH 21, 2025
The pharmaceutical R&D landscape continues to evolve rapidly with advances in computational technologies and artificial intelligence.
Pharmaceuticals Related Topics 
GSK to buy liver disease drug for $1.2B
BioPharma Drive: Drug Pricing
MAY 14, 2025
The new acquisition from Boston Pharmaceuticals adds to a wave of dealmaking undertaken by GSK to build its liver disease franchise.
Disease 
255
255 Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AI-Powered Portfolio Management in Pharmaceuticals
Drug Patent Watch
MAY 19, 2025
"Revolutionizing the Pharmaceutical Industry: How AI-Powered Portfolio Management is Changing the Game As the pharmaceutical landscape continues to evolve, companies are under increasing pressure to optimize their portfolios and stay ahead of the competition. link] #pharmaceuticals #portfoliooptimization #AIinpharma"
Drug pollution alters salmon migration
Science Daily: Pharmacology News
APRIL 10, 2025
Study reveals commonly detected environmental levels of clobazam -- a medication often prescribed for sleep disorders -- increased the river-to-sea migration success of juvenile salmon in the wild.
Pharmaceuticals 264
264 
Generative AI can enhance pharmaceutical innovation – but are you ready for it?
BioPharma Drive: Drug Pricing
SEPTEMBER 16, 2024
There’s no doubt that AI and GenAI can speed up pharmaceutical innovation. But before organizations can jump into the future, it’s crucial to understand the benefits – and the risks – of advanced technology.
Pharmaceuticals 183
183 Pharmaceuticals 183
183 
Sustainability in pharmaceutical manufacturing: a CDMO’s contribution
BioPharma Drive: Drug Pricing
APRIL 29, 2024
Consideration of sustainability early in process development, throughout the entire development cycle, and across the entire supply chain must also become common practice.
Pharmaceuticals 269
269 Pharmaceuticals 269
269 
Effective Drug Patent Prosecution Strategies: Securing Your Pharmaceutical Innovations
Drug Patent Watch
DECEMBER 18, 2024
As a business professional in the pharmaceutical industry, understanding and implementing effective strategies for drug patent prosecution can be the difference between market domination and missed opportunities. Dr. Jane Smith, a patent attorney specializing in pharmaceuticals, advises: “File early and file often. billion[1].
Exploring the Role of South Africa in the Global Pharmaceutical Landscape
Drug Patent Watch
MAY 5, 2025
"As the world grapples with the complexities of global healthcare, one nation is rewriting the rules of the pharmaceutical game: South Africa. From pioneering generic drug production to challenging Big Pharma's dominance, South Africa is redefining what it means to be a leader in the global pharmaceutical landscape.
How AI will reshape pharma by 2025
Drug Target Review
DECEMBER 20, 2024
Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. Looking ahead, 2025 could represent a major turning point for the pharmaceutical sector.
Clinical Trials 128
128 
The Strategic Value of Orange Book Data in Pharmaceutical Competitive Intelligence
Drug Patent Watch
JUNE 17, 2025
"Uncovering Hidden Opportunities: The Secret to Unlocking Pharmaceutical Competitive Intelligence As the pharmaceutical industry continues to evolve, companies are under increasing pressure to stay ahead of the curve. Meet the Orange Book, a treasure trove of data that holds the secrets to pharmaceutical competitive intelligence.
Wave sees RNA editing validation in early trial results
BioPharma Drive: Drug Pricing
OCTOBER 16, 2024
The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.
RNA 358
358 
An RNAi renaissance is creating a new generation of startups
BioPharma Drive: Drug Pricing
NOVEMBER 6, 2024
Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.
RNA 347
347 
A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology
BioPharma Drive: Drug Pricing
SEPTEMBER 4, 2024
But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes. Over the past 10 years, PD1-blocking medicines have transformed cancer care.
Pharmaceutical Negotiations Decoded: Lessons from the Trenches
Drug Patent Watch
JANUARY 14, 2025
In the fast-paced world of pharmaceuticals, negotiations play a pivotal role in shaping the industry’s landscape. Let’s dive into the intricacies of pharmaceutical negotiations, exploring valuable lessons, current trends, and strategies for success.
Investors put $400M into biotech licensing obesity drugs from China
BioPharma Drive: Drug Pricing
MAY 16, 2024
The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.
Licensing 356
356 
The Comprehensive Science and Art of Pharmaceutical Drug Naming
Drug Patent Watch
MARCH 5, 2025
The Secret Language of Medicines: Uncovering the Science Behind Pharmaceutical Drug Names As professionals in the healthcare and pharmaceutical industries, we've all seen them - the long, complex names of medications that seem to defy pronunciation. What do you think is the most challenging aspect of pharmaceutical drug naming?
Science 82
82 
‘No tolerance for failure’: An oral history of the first CRISPR medicine
BioPharma Drive: Drug Pricing
DECEMBER 10, 2023
A new sickle cell disease therapy developed by CRISPR Therapeutics and Vertex Pharmaceuticals is now approved in the U.S. This is the story of how it came to be.
Therapies 356
356 
CRISPR therapy for sickle cell approved by FDA in gene editing milestone
BioPharma Drive: Drug Pricing
DECEMBER 8, 2023
In addition to clearing Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, the FDA also granted an early OK to Bluebird bio’s sickle cell treatment Lyfgenia.
FDA 348
348 
Real-world evidence in pharmaceutical drug development – faster, safer and more relevant?
BioPharma Drive: Drug Pricing
NOVEMBER 13, 2023
Regulatory agencies have set the framework and use cases for RWE. How can these increase the probability of success or efficiency in a pre-clinical and clinical drug development program?
Drug Development 269
269 
CDMO Selection: The Ultimate Checklist
Drug Patent Watch
DECEMBER 11, 2024
This growth has created a competitive landscape where pharmaceutical companies must carefully evaluate and select the right CDMO partner to ensure the success of their projects. Pharmaceutical companies should look for CDMOs with a proven track record of working with various molecules and pharmaceutical companies.
A new, non-opioid pain drug is here. Getting it to patients could be agony.
BioPharma Drive: Drug Pricing
JANUARY 31, 2025
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful biotechs contend with a healthcare system that’s long favored opioids?
Pharmaceuticals 314
314 
ADHD Drug Zenzedi Recalled Over Pill Mixup
Drugs.com
JANUARY 30, 2024
30, 2024 -- The maker of a drug used to treat ADHD and narcolepsy has recalled one lot of the medication after a pill mixup was discovered.The recall notice, issued by Azurity Pharmaceuticals Inc., TUESDAY, Jan. states that one lot of Zenzedi.
Drugs 347
347 
New Business Models for Pharmaceutical Marketing: Transforming Data into Market Domination
Drug Patent Watch
DECEMBER 2, 2024
The traditional marketing models that once dominated the pharmaceutical industry are rapidly becoming obsolete, paving the way for innovative approaches that leverage technology, data, and patient-centricity.
Marketing 83
83 
What if a CRISPR cure isn’t such an easy choice?
BioPharma Drive: Drug Pricing
NOVEMBER 8, 2023
A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.
Therapies 325
325 
Pharmaceutical research on mRNA and CAR T-cell therapy in cancer: Pioneering the future of oncology
BioPharma Drive: Drug Pricing
OCTOBER 21, 2024
Immunotherapy and precision medicine show promise in better fighting cancer. What else does the research tell us?
Research 258
258 
How CDMOs Can Use Patent Data to Win More Pharmaceutical Clients
Drug Patent Watch
JUNE 18, 2025
"Breaking the Patent Code: How CDMOs Can Unlock a Competitive Edge in the Pharmaceutical Market As the pharmaceutical landscape continues to evolve, Contract Development and Manufacturing Organizations (CDMOs) are under increasing pressure to differentiate themselves and attract high-value clients.
World’s first CRISPR medicine approved in UK for sickle cell, beta thalassemia
BioPharma Drive: Drug Pricing
NOVEMBER 16, 2023
Clearance of Vertex Pharmaceuticals and CRISPR Therapeutics' Casgevy in the U.K. comes ahead of expected regulatory decisions in the U.S. and Europe.
Pharmaceuticals 306
306 Pharmaceuticals 306
306 
After surprise trial failure, ALS doctors brace for one less treatment option
BioPharma Drive: Drug Pricing
MARCH 12, 2024
Physicians are preparing for tough conversations with patients on Amylyx Pharmaceuticals’ drug, Relyvrio, while holding out hope it still may help some with the disease.
Doctors 306
306 
Sanofi may have found a buyer for its consumer health business
BioPharma Drive: Drug Pricing
OCTOBER 11, 2024
The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.
Pharmaceuticals 284
284 Pharmaceuticals 284
284 
Employers foresee higher health costs next year due to rising pharmacy spend
BioPharma Drive: Drug Pricing
AUGUST 21, 2024
Pharmaceuticals like the in-demand GLP-1 drugs for obesity are expected to drive increases in healthcare spending in 2025, per a new employer survey.
Pharmacy 277
277 
Startup AIRNA emerges from stealth to bring RNA editing to a rare disease
BioPharma Drive: Drug Pricing
SEPTEMBER 19, 2023
AIRNA is one of several biotechs to debut plans for target alpha-1 antitrypsin deficiency in recent years, with competitors such as AlveoGene, Wave Life Sciences and Arrowhead Pharmaceuticals.
RNA 306
306 
How integrated real-world data helps identify and improve outcomes for rare disease patients
BioPharma Drive: Drug Pricing
APRIL 28, 2025
Pharmaceutical companies are turning to integrated RWD approaches to overcome challenges in rare disease research.
Disease 268
268 
Novel Pharmaceutical Strategies and Business Models: The Rise of Telehealth Companies Like Ro and Hims & Hers
Drug Patent Watch
MAY 5, 2025
But what's driving this transformation, and what does it mean for the future of pharmaceuticals? Read more: [link] "
Lilly weight loss drug approved by FDA
BioPharma Drive: Drug Pricing
NOVEMBER 8, 2023
The pharmaceutical company will sell the GLP-1 drug, branded as Zepbound, at a list price about 20% lower than Novo Nordisk's competing drug Wegovy.
FDA OKs Amvuttra To Treat Heart Conditions
Drugs.com
MARCH 24, 2025
The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals and is used to. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of people.
FDA 279
279 
Pfizer wins FDA approval for its $7B colitis drug
BioPharma Drive: Drug Pricing
OCTOBER 13, 2023
Acquired with the buyout of Arena Pharmaceuticals, Velsipity enters a competitive market for ulcerative colitis pills.
FDA Approval 286
286 
Patent Use Codes for Pharmaceutical Products: A Comprehensive Analysis
Drug Patent Watch
APRIL 17, 2025
"Patent Use Codes: The Hidden Language of Pharmaceutical Innovation As a healthcare professional, have you ever wondered what lies behind the complex world of patent use codes? In this comprehensive analysis, we delve into the world of patent use codes and explore their significance in the pharmaceutical industry.
Experimental Pain Med Could Give Patients New Option to Opioids
Drugs.com
JANUARY 30, 2024
For now, the drug from Vertex Pharmaceuticals is called VX-548. TUESDAY, Jan. 30, 2024 -- The first new kind of pain medication in over two decades could be on the horizon for patients, with promising results announced Tuesday from a company trial.
Pharmaceuticals 297
297 
Biological Characterization of One Oxadiazole Derivative (5(4‐Hydroxyphenyl)‐2‐(N‐Phenyl Amino)‐1,3,4‐Oxadiazole): In Vitro, In Silico, and Network Pharmacological Approaches
Chemical Biology and Drug Design
JANUARY 5, 2025
5(4-Hydroxyphenyl)-2-(N-Phenyl amino)-1,3,4-Oxadiazole (Hppo) can considered as a versatile agent in designing novel pharmaceuticals. Thus, our findings can provide novel and versatile compounds for the development of multidirectional drugs in the pharmaceutical industry.
Bioinformatics 100
100 
India’s Growing Importance in Generic Drug API Manufacturing
Drug Patent Watch
DECEMBER 10, 2024
India has long been recognized as a significant player in the global pharmaceutical industry, particularly in the production of generic drugs. The country’s pharmaceutical sector has experienced substantial growth over the years, driven by both domestic and international demand for affordable and high-quality medicines.
Government 90
90 
Patent box tax incentives pharmaceutical innovation
Drug Patent Watch
MAY 7, 2025
"The Patent Box Tax Incentive: A Game-Changer for Pharmaceutical Innovation? As the pharmaceutical industry continues to drive groundbreaking research and development, a lesser-known tax incentive has emerged as a key catalyst for innovation. But what exactly is the Patent Box, and how is it impacting the pharmaceutical sector?
Poor Trial Results May Prompt Maker to Pull ALS Drug, Relyvrio, From Market
Drugs.com
MARCH 11, 2024
In a statement issued Friday, Amylyx Pharmaceuticals said that Relyvrio failed to help patients in a. MONDAY, March 11, 2024 -- Following disappointing trial results, the maker of a controversial ALS drug may pull the medication off the market.
Marketing 289
289 
Moderna Receives $590M From HHS To Develop Bird Flu Vaccine
Drugs.com
JANUARY 21, 2025
Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu. TUESDAY, Jan. 21, 2025 -- The U.S. This funding, announced Friday by Moderna.
Vaccine 262
262 
Novo Nordisk To Pay $2 Billion for New Weight Loss Drug
Drugs.com
MARCH 25, 2025
TUESDAY, March 25, 2025 -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24. The drug, called UBT251, is being developed.
Let's personalize your content